Analysts think VRCA stock price could increase by 374%
Mar 19, 2025, 11:25 AM
-24.78%
What does VRCA do
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, develops treatments for skin diseases and went public in June 2018. Its pipeline includes YCANTH, VP-315, and VP-103 for various skin conditions.
5 analysts think VRCA stock price will increase by 373.54%. The current median analyst target is $3.06 compared to a current stock price of $0.65. The lowest analysts target is $2.02 and the highest analyst target is $5.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.